(ENTA)—NVS’ equity stake in IDIX was 22% at 12/31/13: http://www.sec.gov/Archives/edgar/data/1093649/000110465914010703/a14-6006_1sc13da.htm At its height, NVS’ stake in IDIX was 56%, but IDIX has had numerous dilutive financings since then in which NVS declined to participate. NVS remains involved in HCV, but its partner of consequence is now ENTA (#msg-90030018, #msg-89752221, #msg-89280314).